29May

Roche’s Ipatasertib (RG7440) in Metastatic Castration-resistant Prostate Cancer (mCRPC)

Roche's Ipatasertib

ASCO 2020 Virtual is happening from May 29 to May 31, and it is exciting to watch major Oncology Pharmaceutical companies and their key presentations.

Roche is worth mentioning here, as it is presenting key poster and study on Ipatasertib in mCRPC.

Ipatasertib (RG7440) Facts:

Ipatasertib is an orally bioavailable inhibitor of the serine/threonine-protein kinase Akt (protein kinase B) with potential antineoplastic activity. Ipatasertib binds to and inhibits the activity of Akt in a non-ATP-competitive manner which may result in the inhibition of the PI3K/Akt signaling pathway and tumor cell proliferation and the induction of tumor cell apoptosis. Activation of the PI3K/Akt signaling pathway is frequently associated with tumorigenesis and dysregulated PI3K/Akt signaling may contribute to tumor resistance to a variety of antineoplastic agents.

Ipatasertib is being studied in tumors that are frequently found to have activation of the PI3K/AKT pathway, including breast and prostate cancers.

As per DelveInsight’s analysis, Ipatasertib + abiraterone acetate will have a significant impact on the market and is expected to generate a noteworthy revenue of more than USD 800 million by 2030 after the successful launch in the market.

Key abstracts/ posters: 
#Abstract 5508:

Circulating tumor DNA (ctDNA) dynamics associate with treatment response and radiological progression-free survival (rPFS): Analyses from a randomized phase II trial in metastatic castration-resistant prostate cancer (mCRPC)

Significance: Analysis of treatment response and radiological progression-free survival (rPFS) of Ipatasertib in mCRPC.